<DOC>
	<DOC>NCT00147745</DOC>
	<brief_summary>This study is designed to assess the potential mechanism of action by which WelCholÂ® (colesevelam) may improve blood glucose control in patients with type 2 diabetes</brief_summary>
	<brief_title>Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Colesevelam Hydrochloride</mesh_term>
	<criteria>Patients between the ages of 18 75, inclusive Diagnosed with type 2 diabetes Hemoglobin A1c value greater than or equal to 8.0% Antidiabetic treatments may include sulfonylurea agents (nonsulfonylurea agents must be withdrawn) Overweight, obese (body mass index 2545 kg/m2) Change of dose of lipid or blood pressure lowering therapy within past three months Previous treatment with colesevelam for hyperlipidemia Serum triglyceride greater than 500 mg/dL Serum low density lipoproteincholesterol less than 60 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Mechanism of action insulin sensitivity</keyword>
</DOC>